Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by T. Van Meerten
Preliminary Results of Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma
Clinical Cancer Research
Cancer Research
Oncology
Outcomes of Patients ≥ 65 Years of Age in Zuma-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Safety and Efficacy of Axicabtagene Ciloleucel (Axi-Cel) in Older Patients: Results From the Us Lymphoma Car-T Consortium
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients With Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up of the Pivotal Zuma-1 Trial
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Safety and Efficacy of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphomas
Therapeutic Advances in Hematology
Hematology
Product Characteristics Associated With in Vivo Expansion of Anti-Cd19 Car T Cells in Patients Treated With Axicabtagene Ciloleucel (Axi-Cel)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Annals of Hematology
Medicine
Hematology
Intravenous Immunoglobulin Therapy Use in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel in the Juliet Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
